This company has been acquired
Prometheus Biosciences Past Earnings Performance
Past criteria checks 0/6
Prometheus Biosciences's earnings have been declining at an average annual rate of -48.4%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been declining at an average rate of 36.5% per year.
Key information
-48.4%
Earnings growth rate
43.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -36.5% |
| Return on equity | -21.6% |
| Net Margin | -3,768.8% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
We Think Prometheus Biosciences (NASDAQ:RXDX) Can Afford To Drive Business Growth
May 17
Here's Why We're Not Too Worried About Prometheus Biosciences' (NASDAQ:RXDX) Cash Burn Situation
Dec 03We Think Prometheus Biosciences (NASDAQ:RXDX) Needs To Drive Business Growth Carefully
Aug 19Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M
Aug 11We're Hopeful That Prometheus Biosciences (NASDAQ:RXDX) Will Use Its Cash Wisely
May 04Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases
Dec 08Prometheus Biosciences (NASDAQ:RXDX) Is In A Good Position To Deliver On Growth Plans
Nov 16Prometheus Biosciences: Precision Medicine For IBD
Sep 22Revenue & Expenses BreakdownBeta
How Prometheus Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 4 | -151 | 45 | 0 |
| 31 Dec 22 | 7 | -142 | 40 | 0 |
| 30 Sep 22 | 7 | -133 | 29 | 0 |
| 30 Jun 22 | 7 | -123 | 29 | 0 |
| 31 Mar 22 | 6 | -108 | 31 | 0 |
| 31 Dec 21 | 3 | -90 | 29 | 0 |
| 30 Sep 21 | 3 | -69 | 25 | 0 |
| 30 Jun 21 | 2 | -50 | 18 | 0 |
| 31 Mar 21 | 2 | -38 | 14 | 0 |
| 31 Dec 20 | 1 | -31 | 11 | 0 |
| 31 Dec 19 | 1 | -17 | 6 | 0 |
Quality Earnings: RXDX is currently unprofitable.
Growing Profit Margin: RXDX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RXDX is unprofitable, and losses have increased over the past 5 years at a rate of 48.4% per year.
Accelerating Growth: Unable to compare RXDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RXDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Return on Equity
High ROE: RXDX has a negative Return on Equity (-21.58%), as it is currently unprofitable.